A phase 3 multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer's Disease (2015-2019)

Professor Gerard Byrne

Mayne Professor of Psychiatry

Medical School

Faculty of Health, Medicine and Behavioural Sciences